JP2020183390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183390A5 JP2020183390A5 JP2020108654A JP2020108654A JP2020183390A5 JP 2020183390 A5 JP2020183390 A5 JP 2020183390A5 JP 2020108654 A JP2020108654 A JP 2020108654A JP 2020108654 A JP2020108654 A JP 2020108654A JP 2020183390 A5 JP2020183390 A5 JP 2020183390A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf11
- antagonist
- pharmaceutical composition
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 21
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 21
- 239000005557 antagonist Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000003247 decreasing effect Effects 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 210000004005 intermediate erythroblast Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718128P | 2012-10-24 | 2012-10-24 | |
| US61/718,128 | 2012-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131952A Division JP2018184430A (ja) | 2012-10-24 | 2018-07-12 | 貧血の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020183390A JP2020183390A (ja) | 2020-11-12 |
| JP2020183390A5 true JP2020183390A5 (enExample) | 2021-03-04 |
Family
ID=50545463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539751A Active JP6401172B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療方法 |
| JP2018131952A Pending JP2018184430A (ja) | 2012-10-24 | 2018-07-12 | 貧血の治療方法 |
| JP2020108654A Withdrawn JP2020183390A (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539751A Active JP6401172B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療方法 |
| JP2018131952A Pending JP2018184430A (ja) | 2012-10-24 | 2018-07-12 | 貧血の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150266950A1 (enExample) |
| EP (2) | EP3527219A1 (enExample) |
| JP (3) | JP6401172B2 (enExample) |
| CN (3) | CN104981250A (enExample) |
| AU (4) | AU2013334660B2 (enExample) |
| CA (1) | CA2889286A1 (enExample) |
| HK (1) | HK1214504A1 (enExample) |
| NZ (1) | NZ747350A (enExample) |
| WO (1) | WO2014066487A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| CN104981250A (zh) * | 2012-10-24 | 2015-10-14 | 细胞基因公司 | 用于治疗贫血的方法 |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| SMT202300166T1 (it) | 2014-12-03 | 2023-07-20 | Celgene Corp | Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| HK1251157A1 (zh) * | 2015-05-13 | 2019-01-25 | 细胞基因公司 | 使用ACTRII配体陷阱治疗β-地中海贫血 |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| MX2019001043A (es) | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
| CN107011430B (zh) * | 2017-04-07 | 2020-09-01 | 哈尔滨医科大学 | 一种具有生物学活性的截短的生长分化因子11及其制备方法 |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN120399032A (zh) | 2018-01-12 | 2025-08-01 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| EP3790572A4 (en) | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF |
| WO2020257587A1 (en) * | 2019-06-19 | 2020-12-24 | Cornell University | Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN113801880B (zh) * | 2021-07-27 | 2024-11-01 | 浙江大学 | 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| CA2194660C (en) * | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| NZ509609A (en) * | 1998-07-28 | 2003-11-28 | Univ Johns Hopkins Med | Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| MXPA04008149A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Proteinas que contienen dominios de folistatina. |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| WO2006105359A2 (en) * | 2005-03-30 | 2006-10-05 | Wyeth | Methods for stimulating hair growth by administering bmps |
| JP2009502121A (ja) * | 2005-07-01 | 2009-01-29 | アクセルロン ファーマ インコーポレーテッド | Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| EP2468291B1 (en) * | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8236751B2 (en) | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| NZ590326A (en) * | 2008-06-26 | 2013-05-31 | Acceleron Pharma Inc | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| ES2796121T3 (es) * | 2009-08-13 | 2020-11-25 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| CN103298832A (zh) * | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| CN104981250A (zh) * | 2012-10-24 | 2015-10-14 | 细胞基因公司 | 用于治疗贫血的方法 |
-
2013
- 2013-10-23 CN CN201380067832.9A patent/CN104981250A/zh active Pending
- 2013-10-23 CN CN202011542063.1A patent/CN112957462A/zh active Pending
- 2013-10-23 EP EP19151143.5A patent/EP3527219A1/en not_active Withdrawn
- 2013-10-23 US US14/438,127 patent/US20150266950A1/en not_active Abandoned
- 2013-10-23 CN CN202011541918.9A patent/CN112933223A/zh active Pending
- 2013-10-23 NZ NZ747350A patent/NZ747350A/en unknown
- 2013-10-23 JP JP2015539751A patent/JP6401172B2/ja active Active
- 2013-10-23 CA CA2889286A patent/CA2889286A1/en not_active Abandoned
- 2013-10-23 AU AU2013334660A patent/AU2013334660B2/en active Active
- 2013-10-23 HK HK16102359.3A patent/HK1214504A1/zh unknown
- 2013-10-23 EP EP13849960.3A patent/EP2911682A4/en not_active Withdrawn
- 2013-10-23 WO PCT/US2013/066353 patent/WO2014066487A2/en not_active Ceased
-
2018
- 2018-07-12 JP JP2018131952A patent/JP2018184430A/ja active Pending
- 2018-11-02 AU AU2018256635A patent/AU2018256635A1/en not_active Abandoned
-
2020
- 2020-05-15 AU AU2020203198A patent/AU2020203198B2/en active Active
- 2020-06-24 JP JP2020108654A patent/JP2020183390A/ja not_active Withdrawn
-
2022
- 2022-03-21 AU AU2022201923A patent/AU2022201923A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183390A5 (enExample) | ||
| JP2016503398A5 (enExample) | ||
| Zhang et al. | Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype | |
| Spina et al. | Antiepileptic drugs: indications other than epilepsy | |
| Greenblatt et al. | Interaction of warfarin with drugs, natural substances, and foods | |
| Zhu et al. | Energy metabolism in cancer stem cells | |
| Zarogoulidis et al. | mTOR pathway: A current, up-to-date mini-review | |
| Burnett et al. | Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model | |
| Wallerstedt et al. | Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment | |
| Yu et al. | Tetramethylpyrazine-mediated suppression of C6 gliomas involves inhibition of chemokine receptor CXCR4 expression | |
| Yao et al. | Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7 | |
| Yan et al. | Pretreatment with AQP4 and NKCC1 inhibitors concurrently attenuated spinal cord edema and tissue damage after spinal cord injury in rats | |
| RU2014110184A (ru) | Комбинации терапевтических средств, предназначенные для лечения рака | |
| Feng et al. | Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase | |
| Park et al. | Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma | |
| Wang et al. | Dexamethasone ameliorates H2S-induced acute lung injury by alleviating matrix metalloproteinase-2 and-9 expression | |
| Nemmar et al. | Diesel exhaust particles induce impairment of vascular and cardiac homeostasis in mice: ameliorative effect of emodin | |
| Awasthi et al. | Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II | |
| D’Alessandro et al. | Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines | |
| Jeannot et al. | Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma | |
| BR112022004587A2 (pt) | Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica | |
| Aoki et al. | Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation | |
| Bauersachs | Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups | |
| Guo et al. | The glutaminase inhibitor compound 968 exhibits potent in vitro and in vivo anti-tumor effects in endometrial cancer | |
| Nishio et al. | Effect of exogenous retinoic acid on tooth movement and periodontium healing following tooth extraction in a rat model |